Accounts in Drug Discovery
Accounts in Drug Discovery describes recent case studies in medicinal chemistry with a particular emphasis on how the inevitable problems that arise during any project can be surmounted or overcome. The Editors cover a wide range of therapeutic areas and medicinal chemistry strategies, including lead optimization starting from high throughput screening "hits" as well as rational, structure-based design. The chapters include "follow-ons" and "next generation" compounds that aim to improve upon first generation agents. This volume surveys the range of challenges commonly faced by medicinal chemistry researchers, including the optimization of metabolism and pharmacokinetics, toxicology, pharmaceutics and pharmacology, including proof of concept in the clinic for novel biological targets. The case studies include medicinal chemistry stories on recently approved and marketed drugs, but also chronicle "near-misses", i.e., exemplary compounds that may have proceeded well into the clinic but for various reasons did not result in a successful registration. As the vast majority of projects fail prior to registration, much can be learned from such narratives. By sharing a wide range of drug discovery experiences and information across the community of medicinal chemists in both industry and academia, we believe that these accounts will provide insights into the art of medicinal chemistry as it is currently practiced and will help to serve the needs of active medicinal chemists.
Accounts in Drug Discovery, The Royal Society of Chemistry, 2010.
Download citation file:
Digital access
Print format
Table of contents
-
The Discovery of the Dipeptidyl Peptidase-4 (DPP4) Inhibitor Onglyza™: From Concept to Marketp1-24ByJeffrey A. Robl;Jeffrey A. RoblBristol-Myers Squibb Research & DevelopmentDepartment of Discovery Chemistry – Metabolic Diseases, P.O. Box 5400Princeton, NJ 08543USASearch for other works by this author on:Lawrence G. HamannLawrence G. HamannBristol-Myers Squibb Research & DevelopmentDepartment of Discovery Chemistry – Metabolic Diseases, P.O. Box 5400Princeton, NJ 08543USASearch for other works by this author on:
-
Chapter 2: The Discovery of Vorapaxar (SCH 530348), a Thrombin Receptor (Protease Activated Receptor-1) Antagonist with Potent Antiplatelet Effectsp25-50BySamuel ChackalamannilSamuel ChackalamannilMerck, 2015 Galloping Hill Rd, Kenilworth, NJ 07033USASearch for other works by this author on:
-
Chapter 3: The Discovery of Piragliatin, a Glucokinase Activatorp51-70ByRamakanth Sarabu;Ramakanth SarabuDepartments of Discovery ChemistryHoffmann-La Roche, 340 Kingsland Street, NutleyNJ 07110USASearch for other works by this author on:Jefferson W. Tilley;Jefferson W. TilleyDepartments of Discovery ChemistryHoffmann-La Roche, 340 Kingsland Street, NutleyNJ 07110USASearch for other works by this author on:Joseph GrimsbyJoseph GrimsbyMetabolic and Vascular DiseasesHoffmann-La Roche, 340 Kingsland Street, NutleyNJ 07110USASearch for other works by this author on:
-
Chapter 4: The Discovery of OSI-906, a Small-molecule Inhibitor of the Insulin-like Growth Factor-1 and Insulin Receptorsp71-102ByMark J. Mulvihill;Mark J. MulvihillOSI Pharmaceuticals, Inc.Broadhollow Bioscience Park, 1 Bioscience Park Drive, FarmingdaleNY 11735USASearch for other works by this author on:Elizabeth BuckElizabeth BuckOSI Pharmaceuticals, Inc.Broadhollow Bioscience Park, 1 Bioscience Park Drive, FarmingdaleNY 11735USASearch for other works by this author on:
-
Chapter 5: The Genesis of the Antibody Conjugate Gemtuzumab Ozogamicin (Mylotarg®) for Acute Myeloid Leukemiap103-119ByPhilip R. HamannPhilip R. HamannAdjunct Professor, John Jay College of Criminal JusticeNew YorkUSASearch for other works by this author on:
-
Chapter 6: Novel Androgen Receptor Antagonists for the Treatment of Prostate Cancerp120-141ByAshvinikumar V. Gavai;Ashvinikumar V. GavaiBristol-Myers Squibb Research and DevelopmentP.O. Box 4000, Princeton, NJ 08543USASearch for other works by this author on:William R. Foster;William R. FosterBristol-Myers Squibb Research and DevelopmentP.O. Box 4000, Princeton, NJ 08543USASearch for other works by this author on:Aaron Balog;Aaron BalogBristol-Myers Squibb Research and DevelopmentP.O. Box 4000, Princeton, NJ 08543USASearch for other works by this author on:Gregory D. ViteGregory D. ViteBristol-Myers Squibb Research and DevelopmentP.O. Box 4000, Princeton, NJ 08543USASearch for other works by this author on:
-
Chapter 7: The Discovery of UK-390957: the Challenge of Targeting a Short Half-life, Rapid Tmax SSRIp142-165ByMark D. Andrews;Mark D. AndrewsWorldwide Medicinal ChemistryPfizer Global Research and Development, Ramsgate Road, SandwichKent CT13 9NJUKSearch for other works by this author on:Donald S. MiddletonDonald S. MiddletonWorldwide Medicinal ChemistryPfizer Global Research and Development, Ramsgate Road, SandwichKent CT13 9NJUKSearch for other works by this author on:
-
Chapter 8: The Discovery of the Long-acting PDE5 Inhibitor PF-489791 for the Treatment of Pulmonary Hypertensionp166-182ByAndrew S. Bell;Andrew S. BellSandwich LaboratoriesPfizer Global Research and Development, SandwichKentCT13 9NJUKSearch for other works by this author on:Michael J. PalmerMichael J. PalmerSandwich LaboratoriesPfizer Global Research and Development, SandwichKentCT13 9NJUKSearch for other works by this author on:
-
Chapter 9: From HTS to Market: the Discovery and Development of Maraviroc, a CCR5 Antagonist for the Treatment of HIVp183-214ByChris Barber;Chris BarberWorldwide Medicinal Chemistry, Pfizer Ltd, SandwichKentCT13 9NJUKSearch for other works by this author on:David PrydeDavid PrydeWorldwide Medicinal Chemistry, Pfizer Ltd, SandwichKentCT13 9NJUKSearch for other works by this author on:
-
Chapter 10: The Discovery of GS-9131, an Amidate Prodrug of a Novel Nucleoside Phosphonate HIV Reverse Transcriptase Inhibitorp215-237ByRichard MackmanRichard MackmanGilead Sciences, Inc., 333 Lakeside DriveFoster CityCA 94404USASearch for other works by this author on:
-
Chapter 11: 2′-F-2′-C-Methyl Nucleosides and Nucleotides for the Treatment of Hepatitis C Virus: from Discovery to the Clinicp238-266ByMichael J. Sofia;Michael J. SofiaPharmasset, Inc., 303A College Road EastPrincetonNJ 08540USASearch for other works by this author on:Phillip A. Furman;Phillip A. FurmanPharmasset, Inc., 303A College Road EastPrincetonNJ 08540USASearch for other works by this author on:William T. SymondsWilliam T. SymondsPharmasset, Inc., 303A College Road EastPrincetonNJ 08540USASearch for other works by this author on:
-
Chapter 12: A Case History on the Challenges of Central Nervous System and Dual Pharmacology Drug Discoveryp267-286ByPaul V. Fish;Paul V. FishPfizer Global Research and Development, Ramsgate Road, SandwichKent CT13 9NJUKSearch for other works by this author on:Anthony Harrison;Anthony HarrisonPfizer Global Research and Development, Ramsgate Road, SandwichKent CT13 9NJUKSearch for other works by this author on:Florian Wakenhut;Florian WakenhutPfizer Global Research and Development, Ramsgate Road, SandwichKent CT13 9NJUKSearch for other works by this author on:Gavin A. WhitlockGavin A. WhitlockPfizer Global Research and Development, Ramsgate Road, SandwichKent CT13 9NJUKSearch for other works by this author on:
-
Chapter 13: The Discovery of TRPV1 Antagonists: Turning up the Heatp287-315ByMark H. NormanMark H. NormanDirector of Medicinal Chemistry, Amgen, Inc., One Amgen Center Drive, Thousand OaksCA 91320USASearch for other works by this author on:
-
Chapter 14: Uncoupling Neuroprotection from Immunosuppression: the Discovery of ILS-920p316-331ByEdmund I. GrazianiEdmund I. GrazianiWorldwide Medicinal ChemistryPfizer Global Research&Development, 455 Eastern Point RoadGrotonCT 06340USASearch for other works by this author on:
-
Chapter 15: Identification of α7 Nicotinic Acetylcholine Receptor Agonists for their Assessment in Improving Cognition in Schizophreniap332-362ByBruce N. Rogers;Bruce N. RogersPfizer Global Research and Development, Groton Laboratories, Eastern Point RoadGrotonCT 06340USASearch for other works by this author on:E. Jon Jacobsen;E. Jon JacobsenPfizer Global Research and Development, Groton Laboratories, Eastern Point RoadGrotonCT 06340USASearch for other works by this author on:Christopher J. O’Donnell;Christopher J. O’DonnellPfizer Global Research and Development, Groton Laboratories, Eastern Point RoadGrotonCT 06340USASearch for other works by this author on:Christopher L. Shaffer;Christopher L. ShafferPfizer Global Research and Development, Groton Laboratories, Eastern Point RoadGrotonCT 06340USASearch for other works by this author on:Daniel P. Walker;Daniel P. WalkerPfizer Global Research and Development, Groton Laboratories, Eastern Point RoadGrotonCT 06340USASearch for other works by this author on:Donn G. WishkaDonn G. WishkaPfizer Global Research and Development, Groton Laboratories, Eastern Point RoadGrotonCT 06340USASearch for other works by this author on:
Spotlight
Advertisement
Advertisement